The information provided on our website is intended for general informational and educational purposes. You should read and review these Terms of Use before accessing or using this website. By accessing or using this site, you acknowledge that you have read, understood and agreed to the Terms of Use Agreement. These Terms of Use are by and between Arbor Pharmaceuticals, LLC and you, someone who uses or accesses one of our websites. When we refer to ourselves as "we" or "Arbor Pharmaceuticals, LLC," we mean our entire company, including any company that we control (for example, a subsidiary that we own).

As-Is Presentation. Arbor Pharmaceuticals, LLC makes no warranty or representation of any kind as to the information or materials on our website. Access to and use of our website and the content thereof is at your own risk. To the maximum extent permitted by law, Arbor Pharmaceuticals, LLC disclaims any and all warranties, express or implied, including warranties of merchantability, title, and fitness for a particular purpose. Neither Arbor Pharmaceuticals, LLC nor any party involved in creating, producing, hosting or delivering this website or its contents shall be liable for any damages, including without limitation: direct, incidental, consequential, indirect, or punitive damages arising out of access to, use of or inability to use the website, or any errors or omissions in the content thereof. This limitation includes damages arising from any viruses or other harmful code that may infect your computer equipment or from malicious persons who may make unauthorized use of the website or its contents.

Linked Information. Our website may contain links or references to other websites designed, maintained, and promoted by third parties over whom Arbor Pharmaceuticals, LLC has no control. Such links are provided merely as a convenience. Similarly, this website may be accessed from third party links over whom Arbor Pharmaceuticals, LLC has no control. Arbor Pharmaceuticals, LLC makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any information contained in such websites and shall have no liability for any damages or injuries of any kind arising from such content or information. Inclusion of any third party link does not imply an endorsement or recommendation by Arbor Pharmaceuticals, LLC. In the event that you follow a link to a website that is for a company or person that is not under our control, you are reminded to read the terms of use and/or legal notice at each such site, as Arbor Pharmaceuticals, LLC is not responsible for how other companies or persons treat your privacy once you leave the Arbor Pharmaceuticals, LLC website.

Medical Information. Our website may contain general medical or healthcare information that is provided for informational purposes only and should not be used in any way for medical diagnosis or treatment. The information provided on this website should be verified by a healthcare professional for accuracy, currency, completeness, and applicability to your situation before being relied upon. You should always obtain advice provided by a doctor or other qualified healthcare professional.

Non-Confidential Communication to Us. Any communication, information, materials, or items that you send to us through the Internet, electronic mail, post on our website, or otherwise, such as any questions, comments, suggestions, or the like, are and will be deemed to be non-confidential and Arbor Pharmaceuticals, LLC shall have no obligation of any kind with respect to the same. This agreement includes and incorporates by this reference, Arbor Pharmaceuticals' Privacy Policy, which you should review so as to understand Arbor Pharmaceuticals' practice and policies regarding the collection and use of information and data.

Use of Ideas You Communicate. In the event and to the extent that you have any right, title, or interest in any intellectual property contained in any communication to us, including (without limitation) moral rights, you hereby grant to Arbor Pharmaceuticals, LLC a worldwide, non-exclusive, transferable, royalty-free, fully paid-up license to use, execute, perform, display, reproduce, modify, distribute, sell, have sold, make, have made, import, export, and create derivative works that Arbor Pharmaceuticals, LLC will own, and to authorize others to do any of the same, for whatever purpose that Arbor Pharmaceuticals, LLC may choose and under all rights, title, and interest that you have, including (without limitation) all intellectual property and moral rights.

Trademarks. All product names, whether or not appearing in large print or with the trademark symbol, and all product logos, are trademarks of Arbor Pharmaceuticals, LLC, its affiliates, related companies, or its licensors or joint venture partners, unless otherwise noted. Gliadel is a registered trademark of Eisai, Inc. The use or misuse of these trademarks or any other materials, except as expressly permitted herein, and strictly within the limitations of any such permission, is expressly prohibited and may be in violation of copyright law, trademark law, the law of slander and libel, the law of privacy and publicity, and communications regulations and statutes.

Copyrights. The entire contents of this website are subject to copyright protection. Copyright ©2014 Arbor Pharmaceuticals, LLC. All rights reserved. The contents of this website may not be copied other than for non-commercial individual reference with all copyright or other proprietary notices retained, and thereafter may not be recopied, reproduced or otherwise redistributed. Except as expressly provided above, you may not otherwise copy, display, download, distribute, modify, reproduce, republish or retransmit any information, text or documents contained in this website or any portion thereof in any electronic medium or in hard copy, or create any derivative work based on such images, text or documents, without the express written consent of Arbor Pharmaceuticals, LLC. Nothing contained herein shall be construed as conferring by implication, estoppel, or otherwise any license or right under any patent or trademark of Arbor Pharmaceuticals, or any third party.

Void Where Prohibited. This website and its contents are intended to comply with the laws and regulations in the United States. While available outside the United States, the content of this website as it pertains to pharmaceutical products is intended for use only by residents of the United States. The laws and regulations of other countries may be different. Any offer for any product or service made on our website is void where prohibited by law.

User Responsibility. By using any of our websites, you agree to indemnify, defend and hold harmless Arbor Pharmaceuticals, LLC, its officers, directors, employees, agents, suppliers, and third party affiliates from and against any and all losses, expenses, damages, and costs, including reasonable attorneys' fee, resulting from any violation by you of these Terms of Use.

Governing Laws. These Terms of Use and your use of the website shall be governed by the laws of the United States of America and the State of Georgia without regard to conflict of law principles. By using this website you agree that any legal action shall be brought exclusively in a federal or state court of competent jurisdiction sitting in the U.S. state of Georgia. If any provision of these Terms of Use is held to be unlawful, void or unenforceable, then such provision shall be severable without affecting the enforceability of all remaining provisions.


GLIADEL Wafer is indicated for the treatment of patients with newly-diagnosed high-grade glioma as an adjunct to surgery and radiation.

GLIADEL Wafer is also indicated for the treatment of patients with recurrent glioblastoma as an adjunct to surgery.



Seizures: Seizures occurred in 37% of patients treated with GLIADEL Wafers for recurrent glioma in the recurrent high-grade glioma trial. New or worsening (treatment emergent) seizures occurred in 20% of patients; 54% of treatment emergent seizures occurred within the first 5 post-operative days. The median time to onset of the first new or worsened post-operative seizure was four days. Institute optimal anti-seizure therapy prior to surgery. Monitor patients for seizures postoperatively.

Intracranial Hypertension: Brain edema occurred in 23% of patients with newly diagnosed glioma treated with GLIADEL Wafers in the newly-diagnosed high-grade glioma trial. Additionally, one GLIADEL-treated patient experienced intracerebral mass effect unresponsive to corticosteroids which led to brain herniation. Monitor patients closely for intracranial hypertension related to brain edema, inflammation, or necrosis of the brain tissue surrounding the resection. In refractory cases, consider re-operation and removal of GLIADEL Wafers or Wafer remnants.

Impaired Neurosurgical Wound Healing: Impaired neurosurgical wound healing including wound dehiscence, delayed wound healing, and subdural, subgaleal, or wound effusions occur with GLIADEL Wafer treatment. In the newly-diagnosed high-grade glioma trial, 16% of GLIADEL Wafer-treated patients with newly diagnosed glioma experienced impaired intracranial wound healing and 5% had cerebrospinal fluid leaks. In the recurrent high-grade glioma trial, 14% of GLIADEL Wafer-treated patients with recurrent high-grade glioma experienced wound healing abnormalities. Monitor patients post-operatively for impaired neurosurgical wound healing.

Meningitis: Meningitis occurred in 4% of patients with recurrent glioma receiving GLIADEL Wafers in the recurrent high-grade glioma trial. Two cases of meningitis were bacterial; one patient required removal of the Wafers four days after implantation; the other developed meningitis following reoperation for recurrent tumor. One case was diagnosed as chemical meningitis and resolved following steroid treatment. In one case the cause was unspecified, but meningitis resolved following antibiotic treatment. Monitor postoperatively for signs of meningitis and central nervous system infection.

Wafer Migration: GLIADEL Wafer migration can occur. To reduce the risk of obstructive hydrocephalus due to wafer migration into the ventricular system, close any communication larger than the diameter of a Wafer between the surgical resection cavity and the ventricular system prior to Wafer implantation. Monitor patients for signs of obstructive hydrocephalus.

Embryo-Fetal Toxicity: GLIADEL Wafers can cause fetal harm when administered to a pregnant woman. Carmustine, the active component of GLIADEL Wafer, is embryotoxic and teratogenic in rats at exposures less than the exposure at the recommended human dose based on body surface area (BSA) and embryotoxic in rabbits at exposures similar to the exposure at the recommended human dose based on BSA. Advise patients of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception for 6 months after implantation of GLIADEL Wafer. Advise males with female partners of reproductive potential to use effective contraception for 3 months following implantation of Gliadel Wafers.


The most common adverse reactions in newly-diagnosed high-grade glioma patients (incidence >10% and between arm difference ≥4%) are cerebral edema, asthenia, nausea, vomiting, constipation, wound healing abnormalities and depression.

The most common adverse reactions in recurrent high-grade glioma patients (incidence >10% and between arm difference ≥4%) are urinary tract infection, wound healing abnormalities and fever.

For additional safety information, please consult the GLIADEL full Prescribing Information.

You are encouraged to report side effects of prescription drugs to Arbor Pharmaceuticals, LLC Medical Information at 1-866-516-4950 or to the FDA at or call 1-800-FDA-1088.

For US Healthcare Professionals Only.